|
|
WHAT'S NEW
Introducing Adalimumab
BÜHLMANN is pleased to announce the launch of Quantum Blue® Adalimumab which is the ONLY rapid test to measure adalimumab in serum samples. The test is designed for the selective measurement of adalimumab by a sandwich immunoassay and produces results in just 15 minutes.
Announcing Enhancements to Quantum Blue® Infliximab
BÜHLMANN is happy to introduce a revised and enhanced version of our Quantum Blue® Infliximab to the market. The changes result in two new beneficial features for users. One new feature is a higher dilution of 1:10 making it possible to increase the measuring range to up to 184 µg/mL for those studying the induction phase. The second new feature is that this assay is now fully validated for biosimilars: CT-P13 (Remsima and Inflectra), as well as SB2 (FLIXABI).
Upcoming Meeting: Digestive Disease Week (DDW) 2018:
Come by Booth 2347 at DDW 2018 and get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolios.
Upcoming Meeting: Canadian Society for Clinical Chemists (CSCC) 2018
Come by Booth 410 at CSCC 2018 to get an update on our Calprotectin, Therapeutic Drug Monitoring, Chemistry, Neuroimmunology, and Cellular Allergy portfolios.
RESOURCES and RESEARCH
Success Story: James Cook Story
At the largest hospital in Tees Valley, serving around 1.5 million patients, Mr. Andrew Teggert and his team at James Cook University Hospital have recently made changes to their faecal calprotectin testing. Learn about Mr. Andrew Teggerts experience with the evolution of their service from BÜHLMANN Quantum Blue® to BÜHLMANN fCAL turbo® and the running of the protocol on the Siemens Advia 2400 XPT.
IBDoc® and Me
Read perspectives and insights from a patient from the UK who has been using IBDoc® since last October and is trying this new tool to monitor his Crohns Disease for one year. He has been documenting his experiences in a blog to share his journey with a unique home test kit to measure his inflammation levels.
CITATIONS
BÜHLMANN Quantum Blue® Infliximab
The New Biosimilar of Infliximab SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays.
BÜHLMANN Quantum Blue® Infliximab
A Pilot Study Using Point of Care Testing for Infliximab and Faecal Calprotectin in IBD Patients.
BÜHLMANN HIGHLIGHTS
Rapid, Clean, Consistent and Safe Sample Preparation
New Design for Total Laboratory Automation (TLA)
CALEX® Cap extraction device is designed to fulfill the requirements and need in the market for convenient and safe stool extraction. BÜHLMANN has strived to provide the best stool extraction option for calprotectin testing and that is evident in this device's innovative design as it offers superior precision and extraction efficiency.
BUHLMANN DIAGNOSTICS CORP
BÜHLMANN is unique, independent, and reliable in every aspect of its business from the outstanding quality of its products, its excellent after-sales services, and its remarkable scientific innovations. The establishment of BDC is a statement of the importance of you, our customers and our commitment to understanding your needs. Our North American affiliate will help us to continue to foster closer relationships with our customers and enhance our customer support interactions as well as meet your requirements for future BÜHLMANN products. Quality is not just a statement, but part of our daily mission.
105 Route 101A, Suite 1,
Amherst, NH 03031 USA
Ph: (844) 300-9799
info@buhlmannlabs.com
www.buhlmannlabs.com
|
|
|
|